MedTrace Logo

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

NCT03004001 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2022-08-19

No results posted yet for this study

Summary

The study purpose is to determine the hypolipidemic effect of Alirocumab co-administered with atorvastatin on levels of triglyceride-rich lipoproteins and LDL compared to monotherapy with atorvastatin in patients with dyslipidemia secondary to nephrotic syndrome.

Conditions

  • Nephrotic Syndrome

Interventions

DRUG

Alirocumab

150 mg biweekly

DRUG

Alirocumab placebo

placebo

DRUG

Atorvastatin

20 mg/day

Sponsors & Collaborators

Principal Investigators

  • Gloria L Vega, PhD · Dallas VAMC

  • Yin Oo, MD · Dallas VA Medical Center

  • Michael Concepcion, MD · Dallas VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03004001 on ClinicalTrials.gov